Volume 20 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
DING Shu-bo, ZHOU Zhen-zhen, LI Ming, HU Wang-yuan. Efficacy of pelvic short-course palliative radiotherapy for advanced rectal cancer[J]. Chinese Journal of General Practice, 2022, 20(1): 27-30. doi: 10.16766/j.cnki.issn.1674-4152.002268
Citation: DING Shu-bo, ZHOU Zhen-zhen, LI Ming, HU Wang-yuan. Efficacy of pelvic short-course palliative radiotherapy for advanced rectal cancer[J]. Chinese Journal of General Practice, 2022, 20(1): 27-30. doi: 10.16766/j.cnki.issn.1674-4152.002268

Efficacy of pelvic short-course palliative radiotherapy for advanced rectal cancer

doi: 10.16766/j.cnki.issn.1674-4152.002268
Funds:

 2020KY1002

 2012-3-010

  • Received Date: 2020-06-29
    Available Online: 2022-03-03
  •   Objective  To evaluate the efficacy and safety of pelvic short-course palliative radiotherapy in advanced rectal cancer with local symptoms, and to provide treatment strategies for palliative radiotherapy for advanced rectal cancer.  Methods  Total 51 patients with advanced rectal cancer who were admitted to Affiliated Jinhua Hospital, Zhejiang University School of Medicine from May 2016 to April 2020 were selected as the research subjects. The age ranged from 43 to 74 years, and the median age was 61 years old. There were 28 males and 23 females. The rates of pain, bleeding and intestinal obstruction in 51 patients were 66.7%(34/51), 68.6%(35/51), 39.2%(20/51), respectively. All 51 patients were underwent pelvic 5 Gy×5F short-course radiotherapy. The changes in the scores of pain, bleeding and intestinal obstruction symptoms before and after treatment were compared using the symptom score of 0-3 method. The side effects of short-course radiotherapy and the duration of symptom relief were assessed.  Results  In 51 cases, the complete and partial relief of pain was 61.8%(21/34) and 29.4%(10/34), the complete and partial relief of rectal hemorrhage was 74.3%(26/35) and 20.0%(7/35), the complete and partial relief of intestinal obstruction was 55.0%(11/20) and 35.0%(7/20), respectively. The overall symptom complete response was 21.6%, and the partial response was 43.1%. The side effects of pelvic radiotherapy were slight. The median effective duration of pain, hemorrhage, and obstruction were 6.5 months, 8.9 months, and 3.8 months, respectively. Five patients with initial unresectable and 8 patients with potentially resectable advanced stage underwent radical surgical resection. One patient with an initial obstruction score of 2 points underwent enterostomy after 5.5 months of radiotherapy. The overall 1-year, 2-year, and 3-year survival rates were 86.3%(44/51), 62.7%(32/51)and 45.1%(23/51), respectively.  Conclusion  The short-course radiotherapy of pelvic 5Gy×5F has a good palliative effect on the advanced rectal cancer. Short-course radiotherapy allows most patients with intestinal obstruction to avoid surgery, improves the radical operation rate of advanced rectal cancer. It has important significance for the transformation treatment of advanced rectal cancer.

     

  • loading
  • [1]
    ERLANDSSON J, HOLM T, PETTERSSON D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm Ⅲ): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial[J]. Lancet Oncol, 2017, 18(3): 336-346. doi: 10.1016/S1470-2045(17)30086-4
    [2]
    CISEŁ B, PIETRZAK L, MICHALSKI W, et al. Long-course preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish Ⅱ study[J]. Ann Oncol, 2019, 30(8): 1298-1303. doi: 10.1093/annonc/mdz186
    [3]
    BAHADOER R R, DIJKSTRA E A, VAN ETTEN B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1): 29-42. doi: 10.1016/S1470-2045(20)30555-6
    [4]
    HOLLIDAY E B, HUNT A, YOU Y N, et al. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma[J]. J Gastrointest Oncol, 2017, 8(6): 990-997. doi: 10.21037/jgo.2017.09.02
    [5]
    LIU Q, SHAN Z, LUO D, et al. Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study[J]. J Cancer, 2019, 10(5): 1216-1225. doi: 10.7150/jca.28768
    [6]
    OSTWAL V, KAPOOR A, ENGINEER R, et al. Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers[J]. South Asian J Cancer, 2019, 8(2): 92-97. doi: 10.4103/sajc.sajc_174_18
    [7]
    PICARDI V, DEODATO F, GUIDO A, et al. Palliative short-course radiation therapy in rectal cancer: A phase 2 study[J]. Int J Radiat Oncol Biol Phys, 2016, 95(4): 1184-1190. doi: 10.1016/j.ijrobp.2016.03.010
    [8]
    RENZ P, WEGNER R E, HASAN S, et al. Survival outcomes after surgical management of the primary tumor with and without radiotherapy for metastatic rectal adenocarcinoma: A National Cancer Database (NCDB) analysis[J]. Clin Colorectal Cancer, 2019, 18(2): e237-e243. doi: 10.1016/j.clcc.2018.12.005
    [9]
    AGAS R A F, CO L B A, JACINTO J C K M, et al. Neoadjuvant radiotherapy versus no radiotherapy for stage Ⅳ rectal cancer: A systematic review and meta-analysis[J]. J Gastrointest Cancer, 2018, 49(4): 389-401. doi: 10.1007/s12029-018-0141-0
    [10]
    WANG G, WANG W L, JIN H J, et al. The effect of primary tumor radiotherapy in patients with nnresectable stage Ⅳ Rectal or Rectosigmoid Cancer: A propensity score matching analysis for survival[J]. Radiat Oncol, 2020, 15(1): 126. doi: 10.1186/s13014-020-01574-8
    [11]
    TENG H W, LIN J K, LIN T C, et al. Planned short-course radiation (scRT) is superior to upfront concurrent chemoradiation (CCRT) in treating metastatic rectal cancer[J]. J Gastrointest Surg, 2020, 24(5): 1092-1100. doi: 10.1007/s11605-019-04256-3
    [12]
    TYC-SZCZEPANIAK D, WYRWICZ L, KEPKA L, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: Long-term results of a phase Ⅱ study[J]. Acta Oncol, 2013, 24(11): 2829-2834.
    [13]
    YOON H I, KOOM W S, KIM T H, et al. Upfront systemic chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases: Outcomes, compliance, and favorable prognostic factors[J]. PLoS One, 2016, 11(8): e0161475. doi: 10.1371/journal.pone.0161475
    [14]
    KIM K H, SHIN S J, CHO M S, et al. A phase Ⅱ study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis[J]. Radiother Oncol, 2016, 118(2): 369-374. doi: 10.1016/j.radonc.2015.11.029
    [15]
    JAIN S, ENGINEER R, OSTWAL V, et al. Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis[J]. Asia Pac J Clin Oncol, 2020, 17(6). DOI: 10.1111/ajco.13305.
    [16]
    SAPIENZA L G, NING M S, JHINGRAN A, et al. Short-course palliative radiation therapy leads to excellent bleeding control: A single centre retrospective study[J]. Clin Transl Radiat Oncol, 2018, 14: 40-46.
    [17]
    FARINA E, MACCHIA G, SIEPE G, et al. Palliative short-course radiotherapy in advanced pelvic cancer: A phase Ⅱ study (SHARON project)[J]. Anticancer Res, 2019, 39(8): 4237-4242. doi: 10.21873/anticanres.13585
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (174) PDF downloads(6) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return